SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Amendment No. 1)
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF
THE SECURITIES EXCHANGE ACT OF 1934
XORTX THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction of incorporation or organization)||(I.R.S. Employer Identification No.)|
|Suite 4000, 421 – 7th Avenue SW, Calgary, Alberta Canada||T2P 4K9|
|(Address of principal executive offices)||(Zip Code)|
Securities to be registered pursuant to Section 12(b) of the Act:
of each class
to be so registered
of each exchange on which |
to be registered
|Common Shares, no par value||The Nasdaq Stock Market LLC|
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐
If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐
Act registration statement or Regulation A offering statement file number to which this form relates:
File No. 333-258741
Securities to be registered pursuant to Section 12(g) of the Act:
(Title of Class)
This Amendment No. 1 to the registration statement on Form 8-A of XORTX Therapeutics Inc. (the “Company”), initially filed on September 29, 2021 (the “Form 8-A”), is filed for the purpose of correcting the name of the exchange on which the Common Shares will be listed. Except as described in the foregoing sentence, no other changes have been made to the Form 8-A.
INFORMATION REQUIRED IN REGISTRATION STATEMENT
|Item 1.||Description of Registrant’s Securities to be Registered.|
The description of the Common Shares, no par value, of XORTX Therapeutics Inc. (the “Registrant”) under the heading “Description of Share Capital” in the prospectus included in the Registrant’s Registration Statement on Form F-1 (File No. 333-258741), as initially filed with the Securities and Exchange Commission on August 12, 2021, including exhibits, as amended on September 16, 2021, and as it may be subsequently amended (the “Registration Statement”), is hereby incorporated by reference. Any form of prospectus that constitutes part of the Registration Statement and is subsequently filed by the Registrant pursuant to Rule 424(b) under the Securities Act of 1933, as amended, shall be deemed to be incorporated by reference herein.
Pursuant to the Instructions as to Exhibits for Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.
|Date: October 1, 2021||XORTX Therapeutics Inc.|
Chief Executive Officer